Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

How our clients use DrugPatentWatch

Generated: May 23, 2017

DrugPatentWatch Database Preview

Cisatracurium besylate - Generic Drug Details

« Back to Dashboard

What are the generic drug sources for cisatracurium besylate and what is the scope of cisatracurium besylate freedom to operate?

Cisatracurium besylate
is the generic ingredient in four branded drugs marketed by Abbvie, Sandoz Inc, Jiangsu Hengrui Med, and Fresenius Kabi Usa, and is included in six NDAs. There is one patent protecting this compound and two Paragraph IV challenges. Additional information is available in the individual branded drug profile pages.

There are nine drug master file entries for cisatracurium besylate. Four suppliers are listed for this compound.

Summary for Generic Name: cisatracurium besylate

Tradenames:4
Patents:1
Applicants:4
NDAs:6
Drug Master File Entries: see list9
Suppliers / Packagers: see list4
Bulk Api Vendors: see list22
Clinical Trials: see list45
Patent Applications: see list267
Drug Prices:see low prices
DailyMed Link:cisatracurium besylate at DailyMed

Pharmacology for Ingredient: cisatracurium besylate

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Abbvie
NIMBEX PRESERVATIVE FREE
cisatracurium besylate
INJECTABLE;INJECTION020551-002Dec 15, 1995APRXYesYes► Subscribe► Subscribe
Fresenius Kabi Usa
CISATRACURIUM BESYLATE PRESERVATIVE FREE
cisatracurium besylate
INJECTABLE;INJECTION203182-001Feb 26, 2015APRXNoNo► Subscribe► Subscribe
Abbvie
NIMBEX PRESERVATIVE FREE
cisatracurium besylate
INJECTABLE;INJECTION020551-003Dec 15, 1995APRXYesYes► Subscribe► Subscribe
Fresenius Kabi Usa
CISATRACURIUM BESYLATE PRESERVATIVE FREE
cisatracurium besylate
INJECTABLE;INJECTION203182-002Feb 26, 2015APRXNoNo► Subscribe► Subscribe
Sandoz Inc
CISATRACURIUM BESYLATE PRESERVATIVE FREE
cisatracurium besylate
INJECTABLE;INJECTION200154-002Feb 3, 2012APRXNoNo► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Subscribe for Complete Access

  • Anticipate P&T budget requirements
  • Analyze global market entry opportunities
  • Identify first generic entrants

► Plans and Pricing

Expired Orange Book Patents

 Available with subscription

Paragraph IV Activity

 Available with subscription

Patent Maintenance

 Available with subscription

Non-Orange Book Patents

 Available with subscription

International Patents

 Available with subscription

Supplementary Protection Certificates

 Available with subscription

« Back to the Dashboard

For more information try a trial or see the database preview and plans and pricing

How our clients use DrugPatentWatch

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot